These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 30558899)

  • 1. The Cancer Immunogram: A Pledge for a Comprehensive Biomarker Approach for Personalized Immunotherapy in Urothelial Cancer.
    Zahoor H; Grivas P
    Eur Urol; 2019 Mar; 75(3):445-447. PubMed ID: 30558899
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemoimmunotherapy in Metastatic Urothelial Carcinoma.
    Geynisman DM; Abbosh PH; Plimack ER; Zibelman M
    Eur Urol; 2018 May; 73(5):760-762. PubMed ID: 29331216
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy.
    Chang SS
    J Urol; 2020 Jun; 203(6):1061. PubMed ID: 32182171
    [No Abstract]   [Full Text] [Related]  

  • 4. Of Chemoimmunotherapy Sequences and Delayed Disease-modifying Activity in Advanced Urothelial Carcinoma: Vetus Fit Novum.
    Necchi A; Anichini A; Sonpavde G
    Eur Urol; 2018 Feb; 73(2):153-155. PubMed ID: 28967552
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of instillations with chemotherapy or immunotherapy following endoscopic resection for upper tract urothelial carcinoma.
    Bachir BG; Kassouf W
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):63-75. PubMed ID: 22149433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prime time for immunotherapy in advanced urothelial cancer.
    Jiang DM; Sridhar SS
    Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():24-32. PubMed ID: 30489031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers for immunotherapy in urological cancers.
    Gust KM; Resch I; D'Andrea D
    Curr Opin Urol; 2018 Jan; 28(1):25-28. PubMed ID: 29120910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma.
    Ikeda S; Hansel DE; Kurzrock R
    Cancer Treat Rev; 2015 Sep; 41(8):699-706. PubMed ID: 26138514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: SH3BGRL3 Protein as a Potential Prognostic Biomarker for Urothelial Carcinoma: A Novel Binding Partner of Epidermal Growth Factor Receptor.
    Chang SS
    J Urol; 2017 Jul; 198(1):40-41. PubMed ID: 28618713
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
    Tripathi A; Plimack ER
    Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular tumor board-urothelial cancer].
    Hupe MC; Gakis G; Seiler R
    Urologe A; 2019 Jul; 58(7):760-767. PubMed ID: 31172245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel therapeutic targets in advanced urothelial carcinoma.
    Rouanne M; Loriot Y; Lebret T; Soria JC
    Crit Rev Oncol Hematol; 2016 Feb; 98():106-15. PubMed ID: 26589398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.
    Black PC; Seiler R
    Eur Urol; 2016 Dec; 70(6):1076. PubMed ID: 27567209
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunomodulatory treatment in urothelial cancer.
    Dreicer R
    Lancet Oncol; 2016 Nov; 17(11):1475-1477. PubMed ID: 27733242
    [No Abstract]   [Full Text] [Related]  

  • 15. Update of systemic immunotherapy for advanced urothelial carcinoma.
    Gartrell BA; He T; Sharma J; Sonpavde G
    Urol Oncol; 2017 Dec; 35(12):678-686. PubMed ID: 29079131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint inhibition: a new beginning for urothelial cancer.
    Rose TL; Milowsky MI
    Lancet Oncol; 2017 Feb; 18(2):160-161. PubMed ID: 28081913
    [No Abstract]   [Full Text] [Related]  

  • 17. [Role of apoptosis in urothelial carcinoma. 1. Role of apoptosis in the development of urothelial carcinoma].
    Savin M; Petronić V
    Srp Arh Celok Lek; 1999; 127(7-8):258-65. PubMed ID: 10624400
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunotherapy for metastatic urothelial carcinoma: status quo and the future.
    Necchi A; Rink M; Giannatempo P; Raggi D; Xylinas E
    Curr Opin Urol; 2018 Jan; 28(1):1-7. PubMed ID: 29028766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current classification of urothelial (transitional cell) carcinoma and its variants].
    Cheng L; Xu JW; Zheng SQ; Sun YL; Ma YY; Zheng J
    Zhonghua Bing Li Xue Za Zhi; 2008 Mar; 37(3):197-201. PubMed ID: 18788601
    [No Abstract]   [Full Text] [Related]  

  • 20. Imaging response assessment of immunotherapy in patients with renal cell and urothelial carcinoma.
    Weiss J; Notohamiprodjo M; Bedke J; Nikolaou K; Kaufmann S
    Curr Opin Urol; 2018 Jan; 28(1):35-41. PubMed ID: 29083998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.